Get the Stockscreener App
0.223
3.59%
-0.0083
Cel-Sci Corp. stock is traded at $0.223, with a volume of 1.61M.
It is down -3.59% in the last 24 hours and down -13.40% over the past month.
CEL-SCI Corporation engages in the research and development of drugs and vaccines. Its lead investigational immunotherapy is Multikine, which is under pivotal phase III clinical trial for the treatment of primary head and neck cancer. The company's Multikine is also used in a Phase I study with the Naval Medical Center, San Diego under a cooperative research and development agreement in HIV/HPV co-infected men and women with peri-anal warts. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza in hospitalized patients; and CEL-2000 and CEL-4000 vaccine product candidates for the treatment of rheumatoid arthritis. CEL-SCI Corporation was founded in 1983 and is headquartered in Vienna, Virginia.
See More
Previous Close:
$0.2313
Open:
$0.2315
24h Volume:
1.61M
Relative Volume:
1.06
Market Cap:
$18.76M
Revenue:
-
Net Income/Loss:
$-26.92M
P/E Ratio:
-0.4373
EPS:
-0.51
Net Cash Flow:
$-18.92M
1W Performance:
-9.64%
1M Performance:
-13.40%
6M Performance:
-60.19%
1Y Performance:
-84.07%
1-Day Range:
$0.2129
$0.2372
1-Week Range:
$0.2129
$0.2697
52-Week Range:
$0.18
$2.2199
Cel-Sci Corp. Stock (CVM) Company Profile
Name
Cel-Sci Corp.
Sector
Industry
Phone
703-506-9460
Address
8229 Boone Boulevard, Suite 802, Vienna, VA
Compare CVM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CVM
Cel-Sci Corp.
|
0.223 | 20.76M | 0 | -26.92M | -18.92M | -0.51 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Cel-Sci Corp. Stock (CVM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-13-20 | Initiated | H.C. Wainwright | Buy |
| Mar-02-15 | Initiated | Dawson James | Buy |
Cel-Sci Corp. Stock (CVM) Latest News
StockNews.com Begins Coverage on CEL-SCI (NYSE:CVM) - Defense World
CEL-SCI Reports Fiscal Second Quarter 2025 Financial Results - Yahoo Finance
Cel-Sci: Fiscal Q2 Earnings Snapshot - Stamford Advocate
CEL-SCI (NYSE:CVM) Earns Sell Rating from Analysts at StockNews.com - Defense World
CEL-SCI Co. (NYSE:CVM) Shares Sold by Geode Capital Management LLC - Defense World
LD Micro 360 Companies --Set to Present this Week. - ACCESS Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
Take off with Cel-Sci Corp (CVM): Get ready for trading - Sete News
Top investors say Ares Management Corp (ARES) ticks everything they need - Sete News
A stock that deserves closer examination: Cel-Sci Corp (CVM) - uspostnews.com
Investing in Cel-Sci Corp (CVM) Is Getting More Attractive - knoxdaily.com
CVM’s Stock Journey: What Investors Need to Know About Cel-Sci Corp’s Performance - investchronicle.com
Curbline Properties Corp (CURB) Becoming More Attractive for Investors - knoxdaily.com
Metric Analysis: Coca-Cola Femsa S.A.B. DE C.V. ADR (KOF)’s Key Ratios in the Limelight - DWinneX
Analyzing Ratios: Cel-Sci Corp (CVM)’s Financial Story Unveiled - DWinneX
Ratios Revealed: Decoding Applied Dna Sciences Inc (APDN)’s Financial Health - DWinneX
CEL-SCI (NYSE:CVM) Coverage Initiated by Analysts at StockNews.com - Defense World
Cel-Sci Corp [AMEX: CVM] Sees Increase in Stock Value - knoxdaily.com
US biotech seeks Saudi approval for cancer treatment - Arabian Gulf Business Insight | AGBI
CEL-SCI to seek Saudi approval for cancer treatment - Investing.com
CEL-SCI Corp To File For Regulatory Approval Of Multikine In Saudi Arabia - marketscreener.com
CEL-SCI's Cancer Drug Eyes Breakthrough Status in Saudi Arabia as MENA Cancer Cases Set to Double - Stock Titan
Market Momentum Report: Cel-Sci Corp (CVM)’s Positive Close at 0.27 - DWinneX
Its Stock Has Paid Off Big Time For Cel-Sci Corp - Sete News
CEL-SCI to File for Regulatory Approval of Multikine in Saudi Arabia—Pursuing Local Partnerships for Commercialization and Manufacturing to Serve Middle East and North Africa Market - Yahoo Finance
An Analysis of Cel-Sci Corp (CVM)’s Potential Price Growth - knoxdaily.com
Parsons Corp [PSN] Investment Appeal on the Rise - knoxdaily.com
Cel-Sci Corp (CVM) presents a great opportunity, but the stock is slightly overvalued - uspostnews.com
StockNews.com Initiates Coverage on CEL-SCI (NYSE:CVM) - Defense World
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
CEL-SCI's Multikine (CVM) Shows Promising Survival Rates in Head and Neck Cancer Study - GuruFocus
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
CVM stock touches 52-week low at $0.18 amid sharp annual decline - Investing.com Australia
CVM stock touches 52-week low at $0.18 amid sharp annual decline By Investing.com - Investing.com South Africa
Breakthrough Cancer Study: New Data Shows 306% Survival Boost for Multikine Treatment - Stock Titan
New Study in the Scientific Journal "Cancer Cell" Supports CEL-SCI’s Strategy to Seek Early Approval for Multikine in Head and Neck Cancer Based on Pre-Surgical Tumor Responses - Yahoo Finance
CEL-SCI (NYSE:CVM) Now Covered by StockNews.com - Defense World
Top Companies in Radiation Therapy Devices (Apr, 2025) - Tracxn
CVM stock touches 52-week low at $0.23 amid sharp annual decline By Investing.com - Investing.com South Africa
CVM stock touches 52-week low at $0.23 amid sharp annual decline - Investing.com Australia
Cel-Sci Corp’s Market Journey: Closing Weak at 0.24, Down -0.08 - DWinneX
Breakthrough: New Cancer Drug Delivers 95% Quality of Life Improvement for Head & Neck Patients - Stock Titan
CEL-SCI Reports New Data: Treatment with Multikine Resulted in up to 95% Improvement in Quality of Life for Head and Neck Cancer Patients - Yahoo Finance
CVM stock touches 52-week low at $0.26 amid sharp annual decline - Investing.com Australia
CVM stock touches 52-week low at $0.26 amid sharp annual decline By Investing.com - Investing.com South Africa
Cel-Sci Corp (CVM) Volatility Hits 12.01%: What Good Investors Need To Be Aware Of - Stocks Register
CEL-SCI announces closing of $2.5 million offering -March 18, 2025 at 05:23 pm EDT - Marketscreener.com
CEL-SCI Secures $2.5M Funding: Major Push for FDA-Designated Cancer Immunotherapy - StockTitan
Why Harrow Shares Are Trading Higher By 23%; Here Are 20 Stocks Moving Premarket - Benzinga
Cel-Sci Corp. Stock (CVM) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.54%
7.58%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):